Eli Lilly and Company and Innovent Biologics, Inc. announced the companies will collaborate
to support the development and potential commercialization of at least
three cancer treatments over the next decade. Innovent is a leading
biopharmaceutical company in China focused on the development and
manufacturing of complex, high-end biologics for both the Asian and
global markets that meet EMA and FDA/cGMP standards. Innovent will lead the development and manufacturing for the China
market, while Lilly will be responsible for commercialization of the
three potential medicines. Innovent also has co-promotion rights.
Innovent will receive a total upfront payment of $56 million. Lilly
could also issue future payments exceeding $400 million for the
pre-clinical immuno-oncology molecule if the product reaches certain
development, regulatory and sales milestones.
Lilly will contribute its cMet monoclonal antibody gene for
possible treatment of non-small cell lung cancer. Innovent will
contribute its monoclonal antibody targeting protein CD-20 for
investigation in hematologic malignancies. Innovent will contribute a pre-clinical immuno-oncology molecule for
development in China. The companies have agreed that Lilly will be
responsible for development, manufacturing and commercialization of this
molecule outside of China.
Lilly will also receive rights to develop and commercialize up
to three pre-clinical bispecific immuno-oncology molecules outside of
China.
No comments:
Post a Comment